Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleClinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
Author(s)Koehler J, Feneberg W, Meier M, Pöllmann W.
Journal, Volume, IssueInt J Neurosci. 2014;124(9):652-6.
Major outcome(s)The mean spasticity decreased by 57%.
IndicationMultiple sclerosis;SpasticityAbstract
MedicationCannabis

This detailed medical charts' data collection study conducted at a multiple sclerosis (MS) clinic in Germany evaluated the effectiveness of tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray in patients with resistant MS spasticity. Over a 15-month timeframe, THC:CBD spray was initiated in 166 patients. Mean follow-up was 9 months. In all, 120 patients remained on treatment for a response rate of 72%. THC:CBD spray was used as add-on therapy in 95 patients and as monotherapy in 25 patients to achieve best-possible therapeutic results. Among responders, the mean spasticity 0-10 numerical rating scale (NRS) score decreased by 57%, from 7.0 before treatment to 3.0 within 10 days of starting THC:CBD spray. The mean dosage was 4 sprays/day. Most patients who withdrew from treatment (40/46) had been receiving THC:CBD spray for less than 60 days. Main reasons for treatment discontinuation were: adverse drug reactions, mainly dizziness, fatigue and oral discomfort (23 patients; 13.9%); lack of efficacy (14 patients; 8.4%); or need for a baclofen pump (9 patients; 5.4%). No new safety signals were noted with THC:CBD spray during the evaluation period. In this routine clinical practice setting at an MS clinic in Germany, THC:CBD spray was effective and well tolerated as add-on therapy or as monotherapy in a relevant proportion of patients with resistant MS spasticity.

Route(s)Sublingual
Dose(s)
Duration (days)
Participants120 patients with spasticity due to multiple sclerosis
DesignOpen study
Type of publicationMedical journal
Address of author(s)Marianne Strauss Klinik , Berg , Germany.
Full textwww.ncbi.nlm.nih.gov/pubmed/24392812

[Back to Overview]  [IACM Homepage]


up